Polyvalent influenza vaccine is a type of influenza vaccine that provides immunity against more than one type of antigen. In the second week after receiving
called polyvalent). A monovalent vaccine is designed to immunize against a single antigen or single microorganism. A multivalent or polyvalent vaccine is
monovalent vaccine targeting the pandemic virus. The Commission on Influenza was asked to propose the composition of the polyvalent vaccine to be used
Prevnar 20 vaccine to prevent pneumococcal disease in children aged six weeks to 17 years. Pneumovax 23 (pneumococcal vaccine polyvalent) was approved
J07AH05 Other meningococcal polyvalent purified polysaccharides antigen J07AH06 Meningococcus B, outer membrane vesicle vaccine J07AH07 Meningococcus C,
combined business with Novartis Influenza Vaccines as Seqirus [Sek-eer-us], creating the world's second-largest influenza vaccine company. In August 2017, the
protein conjugate heptavalent vaccine (PCV7) beginning in February 2000. In the United States, pneumococcal vaccine, polyvalent is indicated for active immunization
examples of vaccines with the aforementioned route of admission include the oral polio vaccine and the nasal spray influenza vaccine. These vaccines can stimulate
genome; this, along with an adjuvanted polyvalent rhinovirus vaccine, shows potential for future development in vaccine treatment. Human rhinovirus can remain
Spearman, Paul; Moore, Martin L. (22 September 2016). "A polyvalent inactivated rhinovirus vaccine is broadly immunogenic in rhesus macaques". Nature Communications